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The new beta-adrenergic antagonists
For many years propranolol (Inderal) was the only beta-antagonist available in Canada. Since 1977 seven new agents, approved for oral administration only, have become available: metoprolol (Betaloc, Lopressor), nadolol (Corgard), atenolol (Tenormin), oxprenolol (Trasicor), pindolol (Visken), timolol (Blocadren, Timoptic), and Labetalol (Trandate). All are related to propranolol, but have important differences in pharmacologic properties. The relative potencies and recommended doses of these agents are listed in the Table, and a summary of their mode of action, uptake, and elimination follows.
Metoprolol
Metoprolol differs from propranolol in being a "cardioselective" (beta j-selective) antagonist 2 -that is, it preferentially blocks betarreceptors. (Betatreceptors are involved in cardiostimulation and lipe~ lysis while betaz-reeeptors mediate bronchodilation and peripheral vasodilation.) Theoretically betatselective agents are superior to non-selective agents in two important area~: a pure betarselective agent should not cause bronchospasm in patients with asthma or chronic obstructive pulmonary disease and should not cause an increase in peripheral vascular resistance (after-load), as seen with a non-selective agent like propranolol. However, it must be stressed that the betas-selectivity of metoprolol is only relative; some degree of beta2-receptor blockade is seen in most patients when the daily dose exceeds 100rag.
Metoprolol is recommended for the control of hypertension and angina pectoris. Although absorption from the gastrointestinal tract is almost complete (over 95 per cent of an oral dose is absorbed), there is extensive first-pass hepatic metabolismthus accounting for only a 50 per cent bioavailability.
It is broken down ~n the liver, y~etding clinically unimportant and inactive metabolltes that are then excreted by the kidneys. The plasma elimination half-life is three to four hours.
Nadolol
Like propranolol, nado/ol is a non-selective betaantagonist; but unlike propranolol, this agent is only weakly lipid-soluble and about 75 per cent of the absorbed dose is excreted unchanged in the urine, with the rest excreted in the bile and other non-renal routes. 3 It can be removed from the body by haemodialysis. Despite its dependence on the kidneys for etimination, nadolol is not contraindicated in patients with renal failure; but its dose must be adjusted accordingly in these patients and the degree of beta-blockade assessed carefully.
Nadolol is also recommended for the control of hypertension and angina peetoris. Compared with pmpranolol, nadolol is relatively poorly absorbed from the gastrointestinal tract -only a third of the given dose is absorbed -but first-pass hepatic metabolism does not occur. Its elimination half-life is 14 to 24 hours in patients with normal renal function. Due to this long elimination half-life, nadolol can be given once daily -a dose schedule that has been shown to improve compliance of the patient. Since the elimination half-life of nadolot is prolonged as renal dysfunction progresses, 4 it is recommended that the dose interval should be adjusted to 24 to 36 hours in patients with moderately severe renal impairment (creatininr clearance between 31 IO 50 ml/min/1.73 m2), 24 to 48 hours in those with severe renal impairment (creatinine clearance between 10 to 30 ml/min!l.73 m2), and 40 to 60 hours in those with very severe renal impairment (creatinine clearance < 10 ml/min/1.73 m2).5
Atenolol
Atenolol, the most recently introduced betaadrenergic antagonist, has properties similar to both metoprolol and nadolol. 8 Like metoprolol, it is a cardioselective (betaFselective) antagonist; and being only weakly lipid-soluble like nadolol, it is largely eliminated in the urine. This agent is recommended only for the treatment of hypertension. Approximately 50 per cent of an oral dose is absorbed from the gastrointestinal tract, and the maximum dose should not exceed 50 mg daily when creatinine clearance is between 15 and 35ml/min/1.73 m 2 or 50 mg every other day when creatinine clearance is less than 15ml/min/1.73 m 2.
Oxprenolol
Oxprenolol is a non-selective beta-antagonist which exhibits intrinsic sympathomimetic (partial agoriist) activities. 6 That is, while it antagonizes competitively the effects of circulating cateeholamines, its interaction with beta-adrenergic receptors causes a weak stimulation of these receptors. As a betaantagonist, an agent with partial agonist activities is as effective as other members of the group in the control of hypertension, myocardial ischaemia and cardiac arrhythrnias; but in contrast to agents without intrinsic sympathomimetic activities, it causes less slowing of resting heart rate and less depression of left venttdeular function through betat stimulation, and can decrease peripheral vascular resistance as well as relax bronchial smooth muscle through beta2 stimulation. Despite these theoretical advantages, however, agents with partial agonist activities should still be used with caution in patients with cardiac dysfunction, atrioventricular conduction abnormalities, peripheral vascular disease and asthma or chronic obstructive lung disease.
In Canada oxprenolol is recommended only for the treatment of hypertension. Oxprenolol is well absorbed f~om the gastrointestinal tract (70-95 per cent). First-pass hepatic metabolism is variable, and bioavailability after an oral dose is between 24 to 60 per cent. Elimination is largely by conjugation in the liver, yielding a glucuronide metabolite which is then excreted by the kidneys. The elimination half-life is two hours, but the pharmacologic effects last up to twelve hours.
Pindolol
Pindolol is another non-selective beta-antagonist with intrinsic sympathomimetic activities that are slightly more potent than those of oxprenolol 7 It is recommended for the treatment of hypertension and control of angina pectoris. Oral absorption is greater than 90 per cent. Since first-pass hepatic metabolism is near non-existent, bioavailability after an oral dose is also around 90 per cent.
Approximately 60 per cent of an oral dose is ultimately broken down to inactive metabolites in the liver, and the rest is excreted unchanged by the kidneys. The plasma elimination half-life is three to four hours and is unaffected by moderate renal impairment, indicating that there is an increase in metabolic clearance as renal clearance is reduced.
Tirnolol
Timolol is another non-selective beta-antagonist without intrinsic sympathomimetic activities. ~ In addition to the control of hypertension and angina pectofis, it is approved for topical application as eye drops in the treatment of open-angle glaucoma. Its ability to reduce intraocular pressure may be related to the inhibition of aqueous formation, but this hypothesis remains to be verified.
Orally admmis:ered timolol is recommended for the treatment of hypertension and the control of angina, More than 90 per cent of an oral dose is absorbed from the gastrointestinal tract; but bioavailability is only 75 per cent, indicating significant first-pass hepatic metabolism. Approximately 80 per cent of a given dose is transformed to inactive metabolites by the liver and the rest eliminated unchanged by renal clearance. The plasma half-life is three to four hours and is unaffected by moderate degrees of renal dysfunction. Although the ophthalmic dose (one drop of 0.25 or 0.5 per cent solution into each affected eye, twice a day) is only a fraction of the dose used in the treatment of hypertension and angina, enough is absorbed systemically to precipitate congestive heart failure and bronchospasm in susceptible patients. 9 Therefore the degree of beta-blockade should be assessed in all ophthalmic surgical patients receiving timolol eye drops. Furthermore, additive systemic effects should be expected when fimolol or another beta-antagonist is administered orally or intravenously in patients receiving timolol eye drops. treatment of hypertension; general release of the intravenous preparation is pending. It is well absorbed from the gastrointestinal tract, but undergoes extensive presyste.mic hepatic metabolism. The bioavailability of oral compared to intravenous labetalol is approximately 25 per cent. The absorbed fraction is mostly conjugated in the liver with glucuronic acid, yielding water soluble metabolites that are rapidly excreted in urine and in faeces. It is of interest to anaesthetists that hepatic and cholestatic jaundice have been reported following treatment with this agent.
Conclusions
In therapeutics, new drugs do not necessarily have advantages over the parent compounds. This is not true with the new beta-adrenergic antagonistscardio-seleetive agents are less likely to cause bronchospasm in patients suffering from asthma or chronic obstructive puhnonary disease; agents with partial agonist activities are safer in patients who have ventricular dysfunction, atrioventricular conduction delay, bronchial asthma, and peripheral vascular complications; and poor lipid-solubility together with elimination via the renal route have improved the duration of action. However, protection against these complications is not complete; dependence on renal excretion has made adjustment of the dose in patients with renal dysfunction mandatory; and propranolol is still the only agent available for intravenous administration. These agents are not entirely free of the side-effects attributed to propranolol. Surgical patients treated with the newly introduced beta-adrenergic antagonists deserve the same anaesthetic care as that delineated for patients treated with propranolol, lo Labetalol Labetalol is unique in having both alpha, and mixed beta receptor blocking activities, 1L Its betaantagonist action is four times as strong as its alpha-antagonist action, and it is capable of lowering peripheral vascular resistance and blood pressure through alpha blockade as well as preventing reflex tachycardia through beta blockade.
This agent is available now in oral form for the
